Table 2.
Univariable and multivariable analyses.
| Univariable analysis |
Multivariable analysis |
|||||||
|---|---|---|---|---|---|---|---|---|
| P value | HR | 95% CI |
P value | HR | 95% CI |
|||
| LL | UL | LL | UL | |||||
| ALI | <0.0001 | 2.748 | 1.595 | 4.734 | 0.041 | 4.779 | 1.068 | 21.380 |
| Age | 0.008 | 0.483 | 0.283 | 0.824 | 0.736 | 1.252 | 0.340 | 4.613 |
| Sex | <0.0001 | 0.247 | 0.130 | 0.469 | 0.252 | 0.165 | 0.008 | 3.584 |
| Pathology | <0.0001 | 0.214 | 0.115 | 0.400 | ||||
| Smoking | <0.0001 | 0.166 | 0.092 | 0.298 | 0.006 | 0.046 | 0.005 | 0.413 |
| BMI < 18.5 | 0.139 | 0.213 | ||||||
| BMI 18.5–24 | 0.048 | 3.379 | 1.013 | 11.270 | 0.100 | 35.686 | 0.504 | 2525.755 |
| BMI ≥ 24 | 0.517 | 1.200 | 0.691 | 2.084 | 0.691 | 0.751 | 0.182 | 3.089 |
| Recurrence | <0.0001 | 0.034 | 0.019 | 0.060 | ||||
| Stage | <0.0001 | 0.019 | ||||||
| Stage IA | 0.920 | 0.000 | 0.000 | 6.661E + 114 | 0.954 | 0.000 | 0.000 | 1.240E + 206 |
| Stage IB–II | <0.0001 | 0.063 | 0.030 | 0.132 | 0.002 | 0.069 | 0.013 | 0.364 |
| Stage IIIA | 0.037 | 0.531 | 0.293 | 0.963 | 0.106 | 0.250 | 0.046 | 1.343 |
| PS | <0.0001 | 0.305 | 0.179 | 0.521 | 0.713 | 0.719 | 0.124 | 4.172 |
| CCI=0–1 | 0.006 | 0.263 | ||||||
| CCI=2 | 0.003 | 0.269 | 0.114 | 0.635 | 0.103 | 12.227 | 0.604 | 247.356 |
| CCI=2–3 | 0.161 | 0.574 | 0.263 | 1.249 | 0.171 | 7.615 | 0.416 | 139.271 |
| Postoperative treatment | 0.564 | 0.836 | 0.455 | 1.537 | ||||
| CRP (mg/L) | 0.267 | 3.129 | 0.417 | 23.492 | ||||
| WBC (×109/L) | 0.516 | 1.194 | 0.698 | 2.043 | ||||
| RBC (×1012/L) | 0.138 | 2.416 | 0.754 | 7.742 | 0.564 | 1.922 | 0.209 | 17.663 |
| NEUT (×109/L) | 0.255 | 1.366 | 0.798 | 2.336 | ||||
| LYMPH (×109/L) | 0.338 | 1.767 | 0.552 | 5.662 | ||||
| HGB (g/L) | 0.055 | 2.462 | 0.981 | 6.181 | 0.266 | 3.359 | 0.397 | 28.460 |
| PLT (×109/L) | 0.437 | 20.862 | 0.010 | 44278.292 | ||||
| MONO (×109/L) | 0.424 | 20.911 | 0.012 | 36194.887 | ||||
| EO (×109/L) | 0.331 | 1.336 | 0.745 | 2.397 | ||||
| BASO (×109/L) | 0.469 | 20.756 | 0.006 | 76791.105 | ||||
| MCV (fL) | 0.068 | 2.291 | 0.942 | 5.570 | 0.004 | 19.577 | 2.612 | 146.740 |
| RDW (%) | 0.086 | 2.894 | 0.860 | 9.738 | 0.033 | 9.028 | 1.197 | 68.071 |
| ALB (g/dL) | 0.002 | 2.396 | 1.392 | 4.126 | 0.399 | 2.105 | 0.374 | 11.853 |
| LDH (U/L) | 0.036 | 2.151 | 1.052 | 4.401 | 0.019 | 9.568 | 1.449 | 63.177 |
| CEA (ng/mL) | 0.110 | 2.611 | 0.805 | 8.471 | ||||
| NSE (ng/mL) | 0.188 | 1.598 | 0.795 | 3.215 | ||||
| CYFRA21-1 (ng/mL) | 0.259 | 1.828 | 0.641 | 5.215 | ||||
| SCC (ng/mL) | <0.0001 | 3.526 | 1.748 | 7.127 | ||||
| NLR | 0.054 | 1.689 | 0.990 | 2.879 | 0.369 | 0.474 | 0.093 | 2.416 |
| LMR | 0.311 | 1.448 | 0.708 | 2.962 | 0.331 | 0.351 | 0.043 | 2.894 |
| PLR | 0.033 | 2.180 | 1.064 | 1.465 | 0.012 | 27.658 | 2.102 | 363.873 |
ALI, advanced lung cancer inflammation index; BMI, body mass index; PS, performance status; CCI, Charlson comorbidity index; CRP, C-reactive protein; WBC, white blood cell; RBC, red blood cell; NEUT, Neutrophil; LYMPH, Lymphocyte; HGB, hemoglobin; PLT, platelet; MONO, monocyte; EO, eosinophil; BASO, basophil; MCV, mean corpuscular volume; RDW, red cell distribution width; ALB, albumin; LDH, lactate dehydrogenase; CEA, carcinoembryonic antigen; NSE, neuron specific enolase; CYFRA21-1, cytokeratin-19 fragment; SCC, squamous cell carcinoma antigen; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PLR, platelet to lymphocyte ratio; HR, hazard ratio; LL, lower limit; UL, upper limit.